Mission Statement
Our mission is to expand treatment options for men undergoing Androgen Deprivation Therapy (ADT) for prostate cancer. We aim to introduce one or more products that match the safety and testosterone-suppressing efficacy of all FDA-approved androgen-suppressing medications currently available in North America. Central to this effort is our pursuit of regulatory support to establish transdermal estradiol (tE2) as a recognized standard-of-care option for prostate cancer patients.
Background
Recently, findings from the PATCH/STAMPEDE trial in the UK indicate that estradiol tE2 provides as good survival for prostate cancer (PCa) patients when used for androgen deprivation therapy (ADT) as the standard, approved drugs for androgen suppression. Furthermore, the PATCH/STAMPEDE research team previously demonstrated that patients have overall better quality of life when on tE2. Patients have, for example, significantly fewer hot flashes, better sleep, less fatigue, and lower risk of osteoporosis.
There are, however, no tE2 products on the market that have been tested and licensed for men with prostate cancer.
What are we doing?
Research…
- on prostate cancer patients’ interest in alternative forms of ADT.
- on the costs and benefits of various tE2 products on the market, and ways to make tE2 products both cheaper and more available to prostate cancer patients.
- in collaboration with scientists in the USA and UK, we are studying the quality of life benefits of estradiol for men on ADT.
Outreach to…
- patients via support organization in Canada the USA, and beyond, with in-person presentations and chat group participation.
- physicians through individual contacts and professional medical societies to inform them of the survival and quality of life benefits of ADT with tE2.
- Pharma to encourage their development of tE2 products, then testing and licensing the products so they can become officially approved standards of care for prostate cancer patients.
Fund raising…
- to generate enough funding through private and public donations to enable the creation and license of one or more tE2 products for men with prostate cancer.
Team Leads and Key Roles
- Robert Watson—Patient engagement, Product Development, Intellectual Property
- Paul Schellhammer—Senior Medical Lead, “Clinical Trialist”
- Richard Wassersug—Program Strategy, Communications
- Erik Wibowo—Preclinical Research, Sexual Health, Symptom Management
- Carly Sears—Project Coordinator and Data Analyst